Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

Iobenguane I 131

No authors listed
In: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006.
.
Free Books & Documents
Review

Iobenguane I 131

No authors listed.
Free Books & Documents

Excerpt

Information in this record refers to the use of iobenguane I 131 (I 131 meta-iodobenzylguanidine; I 131 MIBG) as a diagnostic agent. International agencies state that breastfeeding should be interrupted for more than 3 weeks following diagnostic use of I 131 MIBG.[1,2]After therapeutic dosages, the manufacturer recommends that breastfeeding should be withheld for 80 days after the final dose. These times usually result in permanent discontinuation of breastfeeding for this infant, and cessation of breastfeeding for the current infant is recommended by most experts.[3-6] Patients receiving iobenguane I 131usually receive potassium iodide prior to the diagnostic examination to block their thyroid glands’ uptake of the I-131 that is released from the I 131 MIBG. Iodide may interfere with the infant’s thyroid function.

Nursing mothers should not work with substances containing I 131 in their workplace.[7]

PubMed Disclaimer

References

    1. Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP 2015;44 (2 Suppl):7-321. - PubMed
    1. ARSAC notes for guidance: Good clinical practice in nuclear medicine. Notes for guidance on the clinical administration of radiopharmaceuticals and use of sealed radioactive sources. 2020. https://www.gov.uk/government/publications/arsac-notes-for-guidance - PubMed
    1. Mattsson S, Johansson L, Leide Svegborn S, et al. Radiation dose to patients from radiopharmaceuticals: A compendium of current information related to frequently used substances. ICRP Publication 128. Annex D. Recommendations on breast-feeding interruptions. Ann ICRP 2015;44 (2 Suppl):319-21. - PubMed
    1. Bombardieri E, Giammarile F, Aktolun C, et al. 131I/123I-metaiodobenzylguanidine (mIBG) scintigraphy: Procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging 2010;37:2436-46. - PubMed
    1. International Atomic Energy Agency. Radiation Protection and Safety in Medical Uses of Ionizing Radiation, IAEA Safety Standards Series No. SSG-46, IAEA, Vienna. 2018. https://www.iaea.org/publications/11102/radiation-protection-and-safety-...

LinkOut - more resources